How Does Multiple Myeloma Remission Affect Heart Attack Outcomes?

A study highlighted the interplay between multiple myeloma remission and myocardial infarction (MI) outcomes. The findings were presented at the Society of Hematologic Oncology 2024 Annual Meeting.

In this retrospective analysis, researchers assessed 582,294 adult MI admissions in the Nationwide Inpatient Sample database, focusing on the relationship between MM remission and hospitalization outcomes, including mortality, length of stay, and total charges.

According to the results, survival rates were comparable between MI patients with remitted MM (96.3% survived) and those without MM in remission (95.05% survived). Initially, mean total hospitalization charges were higher for patients with remitted MM ($131,227.50) than for those without ($118,957.80); however, adjusted analysis showed no significant impact of MM remission on total charges.

The researchers noted that the unadjusted analysis showed a longer average length of stay for patients with remitted MM (5.19 days) compared to those without (4.39 days). However, after adjusting for confounders, they noted a statistically significant association, indicating a 1.93-day shorter length of stay for remitted MM patients (P=0.003).

“This study illuminates the interplay between MM remission and MI hospitalization outcomes. While MM remission does not significantly impact mortality or total charges, it may influence resource utilization patterns, evidenced by the observed decrease in length of stay. Further research is warranted to elucidate the underlying factors driving these findings,” the researchers concluded.

Reference

Babu K, Rajarajan S, Anandan V, et al. Beyond the remission: how does beating cancer affect your heart attack outcomes? Impact of multiple myeloma in remission on hospitalization outcomes in patients with acute myocardial infarction: insights from a retrospective analysis of the 2021 National Inpatient Sample database. Abstract #MM-038. Presented at the Society of Hematologic Oncology 2024 Annual Meeting; September 4-7, 2024; Houston, Texas.